724 reports of this reaction
2.4% of all RALTEGRAVIR reports
#8 most reported adverse reaction
MATERNAL EXPOSURE DURING PREGNANCY is the #8 most commonly reported adverse reaction for RALTEGRAVIR, manufactured by Merck Sharp & Dohme LLC. There are 724 FDA adverse event reports linking RALTEGRAVIR to MATERNAL EXPOSURE DURING PREGNANCY. This represents approximately 2.4% of all 29,953 adverse event reports for this drug.
Patients taking RALTEGRAVIR who experience maternal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MATERNAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for RALTEGRAVIR, but still significant enough to appear in the safety profile.
In addition to maternal exposure during pregnancy, the following adverse reactions have been reported for RALTEGRAVIR:
The following drugs have also been linked to maternal exposure during pregnancy in FDA adverse event reports:
MATERNAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 724 FDA reports for RALTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
MATERNAL EXPOSURE DURING PREGNANCY accounts for approximately 2.4% of all adverse event reports for RALTEGRAVIR, making it a notable side effect.
If you experience maternal exposure during pregnancy while taking RALTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.